Medical Equipment for Cancer Management
Breast Cancer

Over the past 25 years, breast cancer incidence rates have risen globally, with the highest rates in the Western world.
NeoScience
Medical Equipment for Cancer Management

Preferential Radio Frequency Ablation Device (PRFA)
Minimally invasive treatment of breast cancer
NeoScience
Medical Equipment for Cancer Management

TriMed® 500

Minimally invasive
treatment of breast cancer
Hand Piece
Minimally invasive treatment of breast cancer

Clinical studies

• 31 patients treated immediately before surgical resection
• 18 patients treated 3 weeks prior to surgical resection
• 5 patients treated only with TriMed without surgical resection
Minimally invasive treatment of breast cancer

Technical Breakthrough

• Development of a treatment unit incorporating unique features
• Preferential destruction of tumor tissue
• Micropulse precision placement hand piece for penetration of hard tumors
• Temperature, Impedance and Perfusion Control

Future applications

• Palliative treatment
• Treatment of rest tumors
Current disadvantages of breast cancer surgical treatment procedures

- Open surgical treatment with increased risk of seeding
- Procedure demands general anesthesia and possible hospital stay
- Unfavorable cosmetic results
- High treatment costs
Improvements of RFA procedures

- Innovative algorithms for treatment control
- Micropulse precision placement of electrode
- Antiseeding for reduced dissemination of viable cancer cells
Radio Frequency Ablation

- Tumor is heated to 70 °C for approximately 10 to 15 minutes
- Tumor is denaturated
- Excellent cosmetic results
Clinical trials

- Clinical trials are estimated to 50-90 patients to achieve CE approval
- Cooperation between Swedish and European hospitals
## Patents

<table>
<thead>
<tr>
<th>Anti-seeding</th>
<th>Number</th>
<th>Country</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>2007229606</td>
<td>Australia</td>
<td>Granted</td>
<td></td>
</tr>
<tr>
<td>2647070</td>
<td>Canada</td>
<td>Granted</td>
<td></td>
</tr>
<tr>
<td>200780010993.9</td>
<td>China</td>
<td>Granted</td>
<td></td>
</tr>
<tr>
<td>07712443.6</td>
<td>Germany</td>
<td>Granted</td>
<td></td>
</tr>
<tr>
<td>07712443.6</td>
<td>Spain</td>
<td>Granted</td>
<td></td>
</tr>
<tr>
<td>07712443.6</td>
<td>France</td>
<td>Granted</td>
<td></td>
</tr>
<tr>
<td>07712443.6</td>
<td>UK</td>
<td>Granted</td>
<td></td>
</tr>
<tr>
<td>07712443.6</td>
<td>Italy</td>
<td>Granted</td>
<td></td>
</tr>
<tr>
<td>2009-501995</td>
<td>Japan</td>
<td>Granted</td>
<td></td>
</tr>
<tr>
<td>07712443.6</td>
<td>Sweden</td>
<td>Granted</td>
<td></td>
</tr>
<tr>
<td>07712443.6</td>
<td>USA</td>
<td>Granted</td>
<td></td>
</tr>
</tbody>
</table>
## Patents

<table>
<thead>
<tr>
<th>PRFA</th>
<th>200580032517.8</th>
<th>China</th>
<th>Granted</th>
</tr>
</thead>
<tbody>
<tr>
<td>04022985.8</td>
<td>Germany</td>
<td>Granted</td>
<td></td>
</tr>
<tr>
<td>04022985.8</td>
<td>Spain</td>
<td>Granted</td>
<td></td>
</tr>
<tr>
<td>04022985.8</td>
<td>France</td>
<td>Granted</td>
<td></td>
</tr>
<tr>
<td>04022985.8</td>
<td>UK</td>
<td>Granted</td>
<td></td>
</tr>
<tr>
<td>04022985.8</td>
<td>Italy</td>
<td>Granted</td>
<td></td>
</tr>
<tr>
<td>04022985.8</td>
<td>Sweden</td>
<td>Granted</td>
<td></td>
</tr>
<tr>
<td>1000/KOLNP/07</td>
<td>India</td>
<td>Granted</td>
<td></td>
</tr>
</tbody>
</table>
Management

Gert Auer  
COB

Hans Herdensjö  
CEO

Hans Wiksell  
CSO

Peter Fagerlin  
CDO
Achievements

Our projects have attracted Swedish and international media over the past years.

- Featured in distinct print media, e.g. The Economist, Nature Review.
- Featured in TV productions, e.g. "Livsviktig" by Folke Rydén.
- Project was chosen to attend a world tour by the Swedish Institute to present "20 most innovative projects" from Sweden.